Director John James Sullivan filed a Form 4 with the SEC on August 17, 2026, disclosing the vesting of restricted stock units and resulting changes in beneficial ownership of Mesa Laboratories Inc /CO/ common stock on August 15, 2026.

Key Highlights

  • RSU vesting: 2,784 Restricted Stock Units (transaction code M) vested on August 15, 2026, at a price of $0, converting to 2,784 shares of common stock.
  • Direct ownership after transaction: Sullivan directly holds 20,618 shares of Mesa Laboratories common stock following the reported transaction.
  • Indirect ownership: An additional 45,110 shares are held indirectly through the Sullivan Family Trust, for which Sullivan's spouse serves as trustee.
  • Trust disclaimer: Sullivan disclaims beneficial ownership of the trust-held securities except to the extent of his pecuniary interest therein, according to the filing.
  • RSU structure: Each RSU represented a contingent right to receive one share of the issuer's common stock, with the vested RSUs now carrying a remaining balance of 0 derivative securities.

Sullivan Family Trust and RSU Vesting Details for Mesa Laboratories Director

According to the Form 4 filed on August 17, 2026, John James Sullivan, a director of Mesa Laboratories Inc /CO/ (NASDAQ:MLAB), reported a transaction dated August 15, 2026. The transaction involved the vesting of 2,784 Restricted Stock Units under transaction code M, described in the filing as "RSUs that vested on August 15, 2026." The conversion or exercise price of the derivative security was listed as $0, and the acquisition price for the resulting common stock was also $0.

Following the vesting event, Sullivan's direct beneficial ownership stands at 20,618 shares of common stock. Separately, the filing reports 45,110 shares held indirectly through a trust identified as the "Sullivan Family Trust," for which Sullivan's spouse serves as trustee. The filing states that Sullivan "disclaims beneficial ownership of the securities held by the trust except to the extent of his pecuniary interest therein."

The Form 4 was signed by John Sakys under Power of Attorney on behalf of John Sullivan and submitted on August 17, 2026. The filing notes that each RSU represented a contingent right to receive one share of the issuer's common stock, and that following the reported transaction, Sullivan holds 0 derivative securities of the RSU series referenced as "Restricted Stock Units - 10."

What Was Disclosed

The filing discloses the August 15, 2026 vesting of 2,784 RSUs held by Mesa Laboratories director John James Sullivan, resulting in direct beneficial ownership of 20,618 shares of common stock and indirect ownership of 45,110 shares through a family trust.